Polyrizon Ltd. Ordinary Shares (PLRZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Polyrizon Ltd. Ordinary Shares (PLRZ) has a cash flow conversion efficiency ratio of -0.099x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.82 Million) by net assets ($18.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Polyrizon Ltd. Ordinary Shares - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Polyrizon Ltd. Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Polyrizon Ltd. Ordinary Shares carry for a breakdown of total debt and financial obligations.
Polyrizon Ltd. Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Polyrizon Ltd. Ordinary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Voyageur Pharmaceuticals Ltd
V:VM
|
-0.295x |
|
CAM Resources Bhd
KLSE:7128
|
0.149x |
|
Omineca Mining and Metals Ltd
V:OMM
|
-0.046x |
|
Hampton Financial Corp
V:HFC
|
-1.435x |
|
Glen Burnie Bancorp
NASDAQ:GLBZ
|
0.020x |
|
Grand Baoxin Auto Group Limited
F:6BA
|
-0.007x |
|
Vo2 Cap Holding AB
ST:VO2
|
0.070x |
|
Klimator AB
ST:KLIMAT
|
-0.111x |
Annual Cash Flow Conversion Efficiency for Polyrizon Ltd. Ordinary Shares (2020–2024)
The table below shows the annual cash flow conversion efficiency of Polyrizon Ltd. Ordinary Shares from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see PLRZ market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $5.29 Million | $-1.15 Million | -0.217x | -107.72% |
| 2023-12-31 | $-191.00K | $-537.00K | 2.812x | +61.94% |
| 2022-12-31 | $-652.00K | $-1.13 Million | 1.736x | -98.94% |
| 2021-12-31 | $-3.00K | $-492.00K | 164.000x | +3694.52% |
| 2020-12-31 | $16.00K | $-73.00K | -4.563x | -- |
About Polyrizon Ltd. Ordinary Shares
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nas… Read more